SCHEMBL13132008

SCHEMBL13132008

COCCCOc1cc(CBr)cc2cc(F)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.34
TDP1 Q9NUW8 2/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
HTR1A P08908 2/20 0.33
SLC6A4 P31645 2/20 0.33
REN P00797 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
USP2 O75604 1/20 0.33
MAPT P10636 4/20 0.33
HPGD P15428 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 2/20 0.32
MAPK1 P28482 2/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13131958 0.86 KDM4E (0.36) L3MBTL1RENKDM4EHSD17B10HPGD
SCHEMBL2808494 0.82 REN (0.45) L3MBTL1TDP1SMN1; SMN2SLC6A4REN
SCHEMBL13132073 0.79 ALDH1A1 (0.42) HTR1AKDM4EMAPTHTR2CHTR2B
SCHEMBL13132007 0.75 L3MBTL1 (0.39) L3MBTL1TDP1SMN1; SMN2HTR1ASLC6A4
SCHEMBL3977294 0.74 L3MBTL1 (0.39) L3MBTL1TDP1SLC6A4RENKDM4E
SCHEMBL13131932 0.73 TSHR (0.42) SMN1; SMN2KDM4EHSD17B10MAPTHPGD
SCHEMBL1039963 0.72 REN (0.48) L3MBTL1TDP1SMN1; SMN2RENMAPT
SCHEMBL13131977 0.71 REN (0.48) L3MBTL1TDP1SMN1; SMN2HTR1ASLC6A4
SCHEMBL13132005 0.71 REN (0.34) L3MBTL1TDP1SMN1; SMN2RENMAPT
SCHEMBL13131990 0.71 TUBB4A (0.36) L3MBTL1TDP1SMN1; SMN2RENKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 L3MBTL1 4737/4885TDP1 4607/4885SMN1; SMN2 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.